Peptides ACE-031 1mg CAS:1621169-52-5

Peptides ACE-031 1mg CAS:1621169-52-5
Product Introduction:
The drug ACE-031, also known as Myostatin inhibitory peptide 7, is a recombinant protein with specific biological activity. It is composed of type IIB activin receptor (ActRIIB) linked to the Fc region of human immunoglobulin IgG1 and is structurally in the form of a soluble activin receptor. The drug ACE-031 has significant inhibitory activity against myostatin and other negative muscle regulators. By binding to these factors, it inhibits their negative effects on muscle growth, thereby effectively promoting muscle growth and repair. The molecular formula of this drug is C133H227N43O33, its molecular weight is relatively large, reaching 2956.49, and it has a certain density. During storage, it needs to be stored at -20°C, protected from light, and dry to maintain its stability and activity. ACE-031 drug is mainly used in the field of scientific research, especially in the research of muscular dystrophic diseases, muscle growth and repair, etc., showing potential application value. For example, in studies related to Duchenne muscular dystrophy (DMD), the drug ACE-031 was used to treat and observe its efficacy.
Send Inquiry
Description
Technical Parameters

  ↵

Product Introduction

Name:ACE-031

Product Benefits:Improve muscle atrophy and muscle weakness

CAS:1621169-52-5

Capacity:1mg/vial

Product Form:White or off-white powder(Peptides)

Shelf Life:2-3Years(The product packaging date shall prevail)

What is ACE-031?

 

ACE-031 (also known as sotatercept) is an experimental biopharmaceutical that belongs to the transforming growth factor β (TGF-β) superfamily receptor protein inhibitor. It mainly promotes muscle growth by inhibiting the TGF-β signaling pathway, so it has potential therapeutic applications in the fields of muscle atrophy and muscle diseases.

 

Physical and chemical properties:

ACE-031 is a recombinant fusion protein composed of a human hormone receptor (ALK5 receptor) and an Fc fragment. Its structure combines the TGF-β receptor and the immunoglobulin (IgG) Fc region to help it exist stably in the body and enhance its biological activity. By binding to the TGF-β receptor, ACE-031 can block the TGF-β signaling pathway and reduce signals that inhibit muscle growth, thereby promoting the proliferation and differentiation of muscle cells.

 

Main functions:

The mechanism of ACE-031 is mainly to enhance muscle generation by inhibiting the TGF-β signaling pathway. Specific effects include:

1. **Promote muscle growth**: ACE-031 promotes the proliferation and differentiation of muscle cells by inhibiting the inhibitory effect of TGF-β in muscle.

2. **Improving muscular dystrophy**: ACE-031 was found in preclinical studies to combat muscle atrophy caused by muscular dystrophy (such as Duchenne muscular dystrophy) and help repair damaged muscles.

3. **Skeletal muscle hypertrophy**: ACE-031 can stimulate satellite cells in muscles, thereby promoting muscle hypertrophy without increasing excessive fibrosis.

 

Dosage and use:

ACE-031 is administered to patients by subcutaneous or intravenous injection. The dose is usually adjusted according to body weight and treatment regimen. In the clinical trial stage, the common dose is injection once every two weeks or once a month, and each injection dose is usually between **1-3 mg/kg**. The specific dose needs to be adjusted according to the treatment response and clinical goals.

 

Half-life and pharmacokinetics:

ACE-031 has a relatively long half-life as a recombinant protein. Studies have shown that its half-life in the body is approximately **10-20 days**, allowing it to be administered at relatively long intervals. Due to the presence of its immunoglobulin (IgG) Fc part, ACE-031 has high stability and can maintain activity in the blood for a long time.

 

Cycle and effect:

The action cycle of ACE-031 usually depends on its long-term administration and sustained TGF-β signaling inhibition. Its effect usually gradually appears within a few weeks to a few months, so the treatment cycle is long and regular assessment of the patient's muscle function and weight changes are required.

 

Application in clinical and research:

1. **Muscular dystrophy**: ACE-031 has shown potential to fight muscular dystrophy in preclinical trials, especially in genetic muscle wasting diseases such as Duchenne muscular dystrophy. It is expected to improve patient function by stimulating muscle growth.

2. **Skeletal muscle hypertrophy**: Studies in healthy individuals and elderly populations have shown that ACE-031 can promote muscle hypertrophy, help increase muscle mass and strength, and has potential benefits especially for the elderly population.

 

Risks and side effects:

ACE-031, as a biopharmaceutical, may cause some side effects, including but not limited to:

1. **Immune response**: Since ACE-031 is a recombinant protein, users may have an immune response to it, manifested as redness and swelling at the injection site, allergic reactions, etc.

2. **Muscle pain and joint discomfort**: In some patients, muscle or joint pain may occur, especially when using high doses.

3. **Potential tumor risk**: Since ACE-031 inhibits the TGF-β signaling pathway, TGF-β plays an important role in regulating cell proliferation and apoptosis, long-term use may have the risk of tumor development and requires careful monitoring.

 

In short, ACE-031 is a potential biopharmaceutical that shows great promise in the treatment of muscle atrophy and related diseases. However, it is still in the clinical research stage and more tests and data are needed to confirm its safety and effectiveness.

37f42ff7e6610a22f2349d28f310c43

 

Working principle of ACE-031

 

ACE-031 (also known as **ACVR2B antibody** or **ACT-032**) is an experimental drug that is primarily used to study the treatment of muscle atrophy and related diseases. It is a monoclonal antibody targeting **ACVR2B** (Activin receptor type 2B) that has the effect of inhibiting the **SMAD2/3 signaling pathway**, which usually plays a negative regulatory role in muscle growth and repair.

 

1. Applicable population

ACE-031 is mainly suitable for the following populations:

- **Muscular dystrophy patients**: including patients with muscular dystrophy (Duchenne muscular dystrophy, DMD) and other muscle degenerative diseases.

- **Muscle mass loss-related diseases**: such as muscle atrophy caused by advanced cancer patients and chronic wasting diseases (such as cancer, AIDS, etc.).

- **Athletes and fitness people**: Although ACE-031 has not yet been approved for use in healthy people, some researchers have shown interest in its potential ability to enhance muscle growth.

 

2. Working Principle

ACE-031 promotes muscle cell proliferation and hypertrophy by inhibiting proteins such as **Activin A** and **GDF-8 (inhibitory factor, myogenesis inhibitor)** that negatively regulate muscle growth. The specific mechanisms include:

- ACE-031 binds to the ACVR2B receptor, blocking the binding of Activin A and GDF-8 to the receptor, thereby reducing their inhibitory effects on muscle generation.

- By reducing factors that inhibit muscle generation, ACE-031 may promote muscle growth and repair, thereby improving muscle mass and strength.

This effect can theoretically help improve the symptoms of patients with muscular dystrophy, but the drug is currently in the clinical research stage and has not been widely approved for clinical use.

 

3. Dosage and Administration

The specific dosage and administration of ACE-031 has not been clearly specified in the formal clinical treatment guidelines because it is still in the clinical trial stage. Depending on the design of the clinical trial, ACE-031 is usually administered in the form of **injection**.

- **Administration method**: intravenous injection (IV), usually under the supervision of medical staff.

- **Dosage and frequency**: The specific dose depends on the design of the clinical trial. For example, the dose range used in early clinical studies was about once every two weeks, with doses increasing gradually from low to high.

However, ACE-031 has not been widely approved for routine clinical treatment, so the specific usage and dosage need to refer to the specific clinical trial protocol.

 

4. Clinical studies and results

ACE-031 has been evaluated in multiple clinical trials, especially in the treatment of **Duchenne muscular dystrophy** (DMD). Early studies have shown that ACE-031 can improve muscle mass, especially in a small number of testers, where muscle strength and size were increased. However, these effects were not sustained in all participants, and the study also reported certain side effects.

 

5. Potential side effects

Although ACE-031 has the potential to improve muscle growth, there are some side effects that need to be noted. Common side effects include:

- Injection site reactions (such as redness, swelling, and pain)

- Allergic reactions

- Changes in blood indicators (such as white blood cell count, abnormal liver and kidney function)

- Muscle-related side effects, such as muscle pain and weakness

 

Summary

ACE-031 is a potential therapeutic drug for muscular dystrophy and other muscle degenerative diseases. It mainly promotes muscle growth by inhibiting proteins that have a negative effect on muscle generation (such as Activin A and GDF-8). It is still in the clinical trial stage and has not yet been widely used in clinical treatment.

1

 

Related benefits of ACE-031

 

ACE-031 (also known as ACE-031 protein or ActRIIB-Fc) is an experimental protein that belongs to a class called "receptor-regulated proteins". It is a candidate drug that increases muscle mass by regulating muscle growth-related pathways. The main mechanism of action of ACE-031 is to improve muscle strength by inhibiting muscle atrophy and enhancing muscle growth, especially in patients with some muscle diseases.

 

1. Mechanism of action of ACE-031

ACE-031 works by binding to and inhibiting the function of the **ActRIIB** receptor. ActRIIB (activator receptor IIb) is a receptor associated with members of the TGF-β (transforming growth factor β) superfamily, which usually regulate muscle growth and degeneration. ACE-031 works by binding to this receptor and inhibiting its signaling, thereby reducing muscle atrophy-related signals and promoting muscle growth and strengthening.

Through this mechanism, ACE-031 is expected to play an important role in the treatment of diseases caused by muscle atrophy or weakness, such as muscular dystrophy, Duchenne muscular dystrophy (DMD), muscle atrophy, etc.

 

2. Potential Benefits of ACE-031

#### 2.1 Enhanced Muscle Growth

ACE-031 has been shown to stimulate the proliferation and differentiation of muscle cells and increase muscle mass by intervening in the TGF-β signaling pathway. In some experiments, ACE-031 has shown a significant effect on increasing muscle mass, especially in animal models, where it helps increase muscle volume and strength and improve muscle function.

#### 2.2 Treatment of Muscular Dystrophy

ACE-031 has significant potential in treating diseases caused by muscle atrophy, especially in diseases such as **Duchenne Muscular Dystrophy (DMD)** and **idiopathic Muscular Dystrophy** (such as ALS, etc.). These diseases usually cause muscles to gradually weaken and atrophy. ACE-031 may help slow the disease process, reduce the loss of muscle mass, and improve patients' motor function by inhibiting signaling pathways associated with muscle decline.

#### 2.3 May Improve Myocardial Health

Some studies have also shown that ACE-031 may play a role in improving myocardial health, especially in conditions such as heart failure. Cardiac muscle is similar to skeletal muscle, and ACE-031 may help repair and restore myocardial function by promoting muscle growth and repair. Although the evidence in this regard is still in its early stages, it provides broad prospects for the potential application of ACE-031.

#### 2.4 Improvement of muscle mass in the elderly

As people age, many people experience a decrease in muscle mass (muscular dystrophy or muscle decline). The muscle growth and enhancement effects of ACE-031 can theoretically help the elderly population restore certain muscle functions, slow down muscle degeneration caused by aging, and thus improve the quality of life, reduce the risk of falls, and improve daily activities.

#### 2.5 Potential for athletes and fitness people

For some people who pursue increasing muscle mass and improving athletic performance, the muscle growth promotion effect of ACE-031 can theoretically help accelerate muscle recovery and growth. This possibility also makes ACE-031 a hot topic in the field of sports medicine. Its application has the potential to improve the muscle recovery process after exercise and help reduce the recovery time after sports injuries.

 

3. Clinical research of ACE-031

The clinical research of ACE-031 is still in the early stage, mainly including several small-scale clinical trials to study its efficacy in different types of muscle diseases (such as DMD, idiopathic muscular dystrophy, etc.).

1. **Study in Duchenne muscular dystrophy**: ACE-031 has been clinically tested in some DMD patients. Preliminary results show that it can significantly increase the muscle volume and strength of patients, although the efficacy may vary from individual to individual. Studies have also found that the side effects of ACE-031 mainly include muscle pain and injection site reactions.

2. **Study in healthy adults and elderly populations**: Some preliminary studies have shown that ACE-031 may have a certain effect on promoting muscle mass in the elderly, especially during the recovery period and reducing muscle decline. However, these research results still need further confirmation.

3. **Side effects and safety evaluation**: Although ACE-031 shows potential in promoting muscle growth, its safety for long-term use also needs to be evaluated. Some studies have shown that ACE-031 may cause side effects such as muscle pain, injection site reactions, and flu-like symptoms.

 

4. Potential risks and challenges

Although ACE-031 has many potential benefits, there are still some risks and challenges that need attention in practical applications:

1. **Risk of side effects**: In clinical trials, ACE-031 showed some side effects, including muscle pain, flu-like symptoms, and reactions at the injection site. For some patients, these side effects may affect the continuity of treatment.

2. **Unknown long-term effects**: At present, the long-term efficacy and side effects of ACE-031 have not been fully clarified, especially whether it can effectively improve muscle mass in the long term without obvious side effects still requires more clinical data to verify.

3. **Ethical issues**: Muscle enhancers like ACE-031 may cause ethical controversy, especially in the fitness and sports world. Some people may question whether such drugs will become a "performance enhancement" tool for athletes or fitness enthusiasts, thus affecting fair competition and ethical issues.

 

5. Future prospects

ACE-031 is still in the research stage as a muscle enhancer and therapeutic drug, but it brings hope to related fields such as the treatment of muscular dystrophy, sports injury recovery and aging. With the accumulation of more clinical data and in-depth research, the clinical application prospects of ACE-031 may be broader, especially in the fields of delaying aging, treating hereditary muscle diseases and promoting exercise recovery.

83

 

Contact Details(WhatsApp  Telegram ) And Payment Methods

 

WhatsApp/Telegram:+852 6749 2648

Gmail:lucasraws207@gmail.com

Skype:live:.cid.8f21dc7fc6621ba7

1729737702523 1729737641865 product-570-257

 

FAQ

Q: What is ACE-031?

A: ACE-031 is an experimental drug that promotes muscle growth by regulating specific muscle growth factors. It increases muscle cell proliferation and growth by inhibiting the TGF-β (transforming growth factor-β) signaling pathway, and has potential therapeutic applications, especially in patients with muscular dystrophy.

Q: What is the mechanism of action of ACE-031?

A: The main mechanism of ACE-031 is to reduce signaling associated with muscle growth inhibition by inhibiting the activity of ActRIIB, a muscle-specific receptor. ActRIIB is part of the TGF-β signaling pathway, which normally inhibits muscle growth. ACE-031 increases muscle proliferation and repair by interfering with this pathway.

Q: What diseases is ACE-031 used to treat?

A: ACE-031 is mainly used to treat diseases related to muscle weakness and atrophy, especially in clinical trials for Duchenne muscular dystrophy (DMD) and other muscle-wasting diseases. DMD is a genetic muscle disease that usually causes children and adolescents to gradually lose the ability to move.

Q: How is the clinical research of ACE-031 progressing?

A: ACE-031 has been tested in some clinical trials, especially in patients with DMD. Early studies have shown that it has potential in increasing muscle mass and strength. However, as the research progresses, it has also been found that ACE-031 may cause some side effects, such as potential adverse effects on the heart and other important organs, which limits its future use.

 

Hot Tags: peptides ace-031 1mg cas:1621169-52-5, China peptides ace-031 1mg cas:1621169-52-5 manufacturers, suppliers, factory, Follistatin 344 Enhance the vitality and growth rate of muscle cells, PT141 CAS 32780 32 8, ACE 031 Add muscle mass and volume, Sermorelin Build muscle and improve cardiovascular function, AOD9604 CAS 221231 10 3, MGF CAS 12020 86 9

Send Inquiry
Auctus Steroid Pharma Co., Ltd
Provide a complete after-sales service guarantee, including product return and exchange policies, quality assurance, etc.
contact us